Phase II study of nab-paclitaxel in combination with carboplatin in patients with refractory small-cell lung cancer
Phase 2
Recruiting
- Conditions
- Refractory small-cell lung cancer
- Registration Number
- JPRN-UMIN000015565
- Lead Sponsor
- Dokkyo Medical University
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 22
Inclusion Criteria
Not provided
Exclusion Criteria
1) Symptomatic brain metastasis 2) Pregnant females, possibly pregnant females, females wishing to become pregnant and nursing mothers. Males that are currently attempting to produce a pregnancy 3) With active double cancer or multicentric cancer 4) Treated with radiotherapy within the past four weeks. 5) With clinically important complications. 6) With pleural effusion or pericardial effusion accumulates which need drainage 7) With the history of hypersensitivity for nab-paclitaxel, CBDCA 8) Main organs had a serious medical risk factor, and the physicians judged treatment not to be safe. 9) Physician concludes that the patient's participation in this trial is inappropriate
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method